Potential new target for cancer treatment

In many forms of cancer the growth of tumors and their capacity to spread is stimulated by a number of CAAX proteins. This has led to intensive research into how to block the activity of these proteins.

“The enzyme we are studying develops CAAX proteins so that they will take on the properties that stimulate cancer growth. By blocking this enzyme, we may be able to reduce the modification of CAAX proteins in a new cancer model in mice,” says Associate Professor Martin Bergö, who directs this research at the Wallenberg Laboratory, Sahlgrenska Academy.

The research team uses a genetically modified mouse that produces a muted and constantly active CAAX protein. This is a new model for an extremely aggressive lung cancer and a mild form of blood cancer. In these mice, the production of an enzyme called GGTas1 can also be stopped.

“When we inhibited the production of the enzyme, tumor development decreased dramatically. The mice survived considerably longer, and all signs of blood cancer disappeared. A drug that blocks this enzyme can be an effective future cancer treatment,” says Martin Bergö.

The findings strongly indicate that the enzyme GGTas1 is a promising target for cancer treatment. At the cell level, inhibition of the enzyme resulted in blocked cell growth and decreased cell mobility.

“Another interesting discovery in this study was that many types of cells appear to be able to survive without the enzyme. This is important from the point of view of toxicology, since you want a drug to attack only the cancer cells and not normal cells and tissues,” says Martin Bergö.

The research team is now pursuing the question of whether GGTas1 can also be an effective target for treating other types of cancer. They will also be ensuring that inhibiting this enzyme does not damage other cell types and tissues.

For more information, please contact: Associate Professor Martin Bergö, phone: +46(0)31-342 78 58; e-mail: martin.bergo@wlab.gu.se Journal: Journal of Clinical Investigation Title of article: GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer Authors: Anna-Karin M. Sjögren, Karin M.E. Andersson, Meng Liu, Briony A. Cutts, Christin Karlsson, Annika M. Wahlström, Martin Dalin, Carolyn Weinbaum, Patrick J. Casey, Andrej Tarkowski, Birgitta Swolin, Stephen G. Young, Martin O. Bergö

Media Contact

Elin Lindström Claessen idw

More Information:

http://www.vr.se

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Superradiant atoms could push the boundaries of how precisely time can be measured

Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…

Ion thermoelectric conversion devices for near room temperature

The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…

Zap Energy achieves 37-million-degree temperatures in a compact device

New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…

Partners & Sponsors